Naples Global Advisors LLC lessened its position in shares of GlaxoSmithKline plc (NYSE:GSK) by 23.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,414 shares of the pharmaceutical company’s stock after selling 6,435 shares during the quarter. Naples Global Advisors LLC’s holdings in GlaxoSmithKline were worth $760,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Wealthcare Advisory Partners LLC increased its position in GlaxoSmithKline by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the last quarter. FTB Advisors Inc. increased its position in GlaxoSmithKline by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares during the last quarter. Advisory Services Network LLC increased its position in GlaxoSmithKline by 24.2% during the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares during the last quarter. Quadrant Capital Group LLC increased its position in GlaxoSmithKline by 3.5% during the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares during the last quarter. Finally, Waldron LP purchased a new stake in GlaxoSmithKline during the third quarter valued at $203,000. Institutional investors own 9.80% of the company’s stock.
GSK has been the subject of a number of analyst reports. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 24th. Zacks Investment Research cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Wednesday, January 10th. Investec cut GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. TheStreet upgraded GlaxoSmithKline from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, Bank of America cut GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $38.57.
Shares of GlaxoSmithKline plc (NYSE GSK) opened at $38.20 on Friday. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The company has a market capitalization of $94,622.44, a PE ratio of 31.31, a price-to-earnings-growth ratio of 2.36 and a beta of 0.98. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $44.53.
GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.01. GlaxoSmithKline had a return on equity of 115.30% and a net margin of 7.79%. sell-side analysts expect that GlaxoSmithKline plc will post 2.91 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, January 11th. Stockholders of record on Friday, November 10th were paid a $0.5037 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.27%. GlaxoSmithKline’s dividend payout ratio is 167.21%.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline acquired 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was purchased at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Naples Global Advisors LLC Trims Position in GlaxoSmithKline plc (GSK)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/20/naples-global-advisors-llc-trims-position-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.